Eli Lilly (LLY) cash flow statement

Pharmaceuticals · NYSE · Health Care

$1,416 -1.13% Close Nov 17, 2026 Live

TrendArc score 100 of 100 · Health 9.3 · Momentum 9.2 · Moat 8.4 · scored Nov 17, 2026 · How the score works

Free cash flow, fiscal year to December 31, 2025

$9.0 billion

up 138.6% from the year before

Eli Lilly generated $9.0 billion of free cash flow in the fiscal year to December 2025: $16.8 billion of cash from operations less $7.8 billion of capital spending. That was 13.8% of revenue, against 8.3% the year before. Over the last four quarters, to September 30, 2026, it was $19.7 billion.

What stands out

  • Net share repurchases of $4.1 billion and dividends of $5.4 billion came to 106% of free cash flow in the fiscal year to December 2025.
  • Cash dividends paid rose in each of the last five fiscal years, from $2.7 billion to $5.4 billion in total.

Each sentence is written by a fixed rule from the figures on this page.

Free cash flow and net income, the last 10 fiscal years

-$10.0B$10.0B$20.0B$30.0B2016201720182019202020212022202320242025$3.89BFree cash flow $8.97BNet income $20.6B-$10.0B$10.0B$20.0B$30.0B20172019202120232025Free cash flow $8.97BNet income $20.6B

Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.

Where the cash wentFiscal year to December 31, 2025

  1. Cash from operations 16.8
  2. Capital spending -7.8
  3. Free cash flow 9.0
  4. Businesses bought and sold, net -0.7
  5. Investments bought and sold, net 0.3
  6. Net share repurchases -4.1
  7. Dividends -5.4
  8. Debt and other 4.9
  9. Net change in cash 4.0

In billions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.

Cash flow statement, the last 10 fiscal years

In billions of US dollars. Each column is a fiscal year, named by the month it ended; the first column adds up the last four quarters. Cash paid out is a negative number.
Fiscal year toLast 4 quarters
to Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Operating activities
Net income20.610.65.26.25.66.28.33.2-0.22.7
Depreciation and amortisation2.01.81.51.51.51.31.21.61.61.5
Stock-based pay0.70.60.60.60.40.30.30.30.30.30.3
Working capital and other items-6.5-4.2-3.2-0.6-0.1-1.3-5.00.44.00.4
Cash from operations30.616.88.84.27.67.46.54.85.55.64.9
Investing activities
Capital spending-11.0-7.8-5.1-3.4-1.9-1.3-1.4-1.0-1.2-1.1-1.0
Businesses bought and sold, net-0.7-0.9-1.0-0.3-0.7-0.8-6.90.0-0.90.0
Investments bought and sold, net0.3-0.3-0.2-0.2-0.20.50.55.1-0.6-1.9
Other investing-2.8-3.0-2.4-1.3-0.6-0.5-0.6-2.0-1.3-0.2
Cash from investing-11.0-9.3-7.2-3.8-2.9-2.3-8.11.9-3.8-3.1
Financing activities
Debt issued or repaid, net8.18.98.7-0.10.50.34.7-0.73.02.5
Shares issued less bought back-5.8-4.1-2.5-0.8-1.5-1.3-0.5-4.4-4.2-0.3-0.6
Dividends paid-6.0-5.4-4.7-4.1-3.5-3.1-2.7-2.4-2.3-2.2-2.2
Other financing-0.8-0.5-0.3-0.3-0.3-0.2-0.21.3-0.4-0.3
Cash from financing-2.21.23.5-5.4-4.1-3.1-2.3-5.90.1-0.6
Exchange rate effect0.4-0.30.2-0.2-0.20.2-0.1-0.10.0-0.2
Net change in cash4.00.40.8-1.80.21.3-5.71.52.00.9
Free cash flow
Free cash flow19.79.03.8—c5.76.15.13.84.34.53.9
Free cash flow margin22.7%13.8%8.3%—20.1%21.4%20.8%17.0%20.1%22.7%18.3%
Free cash flow per share$9.98$4.16—$6.34$6.64$5.60$4.06$4.17—$3.66

c: that year's capital spending line leaves out a large investing outflow (more than half of cash from operations in no named line), so no free cash flow is shown rather than one that is too high.

Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.

Eli Lilly against its peers

CompanyFiscal year toFree cash flowFree cash flow margin
Bristol Myers SquibbBMY Dec 2025$12.8B26.7%
ZoetisZTS Dec 2025$2.28B24.1%
Johnson & JohnsonJNJ Dec 2025$19.7B20.9%
MerckMRK Dec 2025$12.4B19.0%
Corcept TherapeuticsCORT Dec 2025$142M18.6%
PfizerPFE Dec 2025$9.07B14.5%
ViatrisVTRS Dec 2025$1.97B13.8%
Eli LillyLLY Dec 2025$8.97B13.8%
Peer median19.0%

Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.

Next

Follow Eli Lilly with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Eli Lilly from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.